a public good project by the
Synthesis
Company
of California

© 2026

Ruth Ruddle | doi.page

0 works0 citations0 h-index

Ruth Ruddle

Institute of Cancer Research(GB)Cancer Research UK(GB)Cancer Research UK Clinical Trials Unit(GB)

Publications by Year

Research Areas

PI3K/AKT/mTOR signaling in cancer, Computational Drug Discovery Methods, Cancer-related gene regulation, Lung Cancer Treatments and Mutations, Ovarian cancer diagnosis and treatment

Most-Cited Works

→ Combined MYC and P53 Defects Emerge at Medulloblastoma Relapse and Define Rapidly Progressive, Therapeutically Targetable Disease(2014)207 cited
→ Dual Blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) Pathways Synergistically Inhibits Rhabdomyosarcoma Cell Growth In Vitro and In Vivo(2013)150 cited
→ Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2 - and Non– BRCA1/2 -Mutant Cancers(2020)130 cited
→ ALK2 inhibitors display beneficial effects in preclinical models of ACVR1 mutant diffuse intrinsic pontine glioma(2019)118 cited
→ Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance(2023)112 cited
→ A Useful Approach to Identify Novel Small-Molecule Inhibitors of Wnt-Dependent Transcription(2010)103 cited

→ Identification of 4-(4-Aminopiperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidines as Selective Inhibitors of Protein Kinase B through Fragment Elaboration(2008)99 cited

→ A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer(2020)86 cited

→ Preclinical Pharmacology, Antitumor Activity, and Development of Pharmacodynamic Markers for the Novel, Potent AKT Inhibitor CCT128930(2010)86 cited

→ Discovery of 4-Amino-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides As Selective, Orally Active Inhibitors of Protein Kinase B (Akt)(2010)83 cited